Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287521 · ClinicalTrials.gov registry record · Phase 2
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 87
- Enrollment target
NCT00287521: Completed Phase 2 study, sponsored by Alcon Research.
NCT00287521 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 87 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00287521, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG AL-37807 Ophthalmic Suspension, 1.0%
- DRUG Latanoprost, 0.005% (Xalatan)
- OTHER AL-37807 Vehicle
- DRUG Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
What the finished NCT00287521 record still lists
NCT00287521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 4 interventions - of which AL-37807 Ophthalmic Suspension, 1.0% is the first listed.
NCT00287521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00287521 about?
NCT00287521 is a clinical study titled "A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT00287521?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2005-11. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00287521?
The interventions under investigation include: AL-37807 Ophthalmic Suspension, 1.0% (DRUG), Latanoprost, 0.005% (Xalatan) (DRUG), AL-37807 Vehicle (OTHER), Timolol Maleate Ophthalmic Gel Forming Solution, 0.5% (DRUG).
Who is sponsoring clinical trial NCT00287521?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00287521's enrollment target sits among peer trials
87 810th of 2000 higher than 1,189 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia